These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 30860681)
1. Tapentadol in an Experimental Animal Model of Acute Orofacial Pain. Fricova J; Rokyta R; Nedvidek J Neuro Endocrinol Lett; 2019 Feb; 39(7):496-500. PubMed ID: 30860681 [TBL] [Abstract][Full Text] [Related]
2. Effect of tapentadol on experimental model of orofacial pain - a pilot study. Fricová J; Lainczová H; Nedvídek J; Rokyta R Physiol Res; 2020 Dec; 69(Suppl 3):S533-S537. PubMed ID: 33476175 [TBL] [Abstract][Full Text] [Related]
3. Spinal-supraspinal and intrinsic μ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice. Christoph T; Schröder W; Tallarida RJ; De Vry J; Tzschentke TM J Pharmacol Exp Ther; 2013 Dec; 347(3):794-801. PubMed ID: 24051022 [TBL] [Abstract][Full Text] [Related]
4. The influence of μ-opioid and noradrenaline reuptake inhibition in the modulation of pain responsive neurones in the central amygdala by tapentadol in rats with neuropathy. Gonçalves L; Friend LV; Dickenson AH Eur J Pharmacol; 2015 Feb; 749():151-60. PubMed ID: 25576174 [TBL] [Abstract][Full Text] [Related]
5. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain. Schiene K; De Vry J; Tzschentke TM J Pharmacol Exp Ther; 2011 Nov; 339(2):537-44. PubMed ID: 21816956 [TBL] [Abstract][Full Text] [Related]
6. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Schröder W; Vry JD; Tzschentke TM; Jahnel U; Christoph T Eur J Pain; 2010 Sep; 14(8):814-21. PubMed ID: 20541444 [TBL] [Abstract][Full Text] [Related]
8. Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain. Christoph T; De Vry J; Tzschentke TM Neurosci Lett; 2010 Feb; 470(2):91-4. PubMed ID: 20026182 [TBL] [Abstract][Full Text] [Related]
9. Opioid and noradrenergic contributions of tapentadol to the inhibition of locus coeruleus neurons in the streptozotocin rat model of polyneuropathic pain. Torres-Sanchez S; Borges GDS; Mico JA; Berrocoso E Neuropharmacology; 2018 Jun; 135():202-210. PubMed ID: 29551688 [TBL] [Abstract][Full Text] [Related]
10. The Antinociceptive Effect of a Tapentadol-Ketorolac Combination in a Mouse Model of Trigeminal Pain is Mediated by Opioid Receptors and ATP-Sensitive K Barreras-Espinoza I; Soto-Zambrano JA; Serafín-Higuera N; Zapata-Morales R; Alonso-Castro Á; Bologna-Molina R; Granados-Soto V; Isiordia-Espinoza MA Drug Dev Res; 2017 Feb; 78(1):63-70. PubMed ID: 27987222 [TBL] [Abstract][Full Text] [Related]
11. Tapentadol: an analgesic that differs from classic opioids due to its noradrenergic mechanism of action. Caputi FF; Nicora M; Simeone R; Candeletti S; Romualdi P Minerva Med; 2019 Feb; 110(1):62-78. PubMed ID: 30667206 [TBL] [Abstract][Full Text] [Related]
12. Tapentadol for pain: a treatment evaluation. Hartrick CT; Rodríguez Hernandez JR Expert Opin Pharmacother; 2012 Feb; 13(2):283-6. PubMed ID: 22192161 [TBL] [Abstract][Full Text] [Related]
13. Modulation of sensitization processes in the management of pain and the importance of descending pathways: a role for tapentadol? Caraci F; Coluzzi F; Marinangeli F; Mercadante S; Rinonapoli G; Romualdi P; Nicora M; Dickenson AH Curr Med Res Opin; 2020 Jun; 36(6):1015-1024. PubMed ID: 32216591 [No Abstract] [Full Text] [Related]
14. Unique pharmacology of tapentadol for treating acute and chronic pain. Knezevic NN; Tverdohleb T; Knezevic I; Candido KD Expert Opin Drug Metab Toxicol; 2015; 11(9):1475-92. PubMed ID: 26215077 [TBL] [Abstract][Full Text] [Related]
15. Use of a novel thermal operant behavioral assay for characterization of orofacial pain sensitivity. Neubert JK; Widmer CG; Malphurs W; Rossi HL; Vierck CJ; Caudle RM Pain; 2005 Aug; 116(3):386-395. PubMed ID: 15982812 [TBL] [Abstract][Full Text] [Related]
16. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. Schröder W; Tzschentke TM; Terlinden R; De Vry J; Jahnel U; Christoph T; Tallarida RJ J Pharmacol Exp Ther; 2011 Apr; 337(1):312-20. PubMed ID: 21262850 [TBL] [Abstract][Full Text] [Related]
17. Lack of synergistic interaction between the two mechanisms of action of tapentadol in gastrointestinal transit. Cowan A; Raffa RB; Tallarida CS; Tallarida RJ; Christoph T; Schröder W; Tzschentke TM Eur J Pain; 2014 Sep; 18(8):1148-56. PubMed ID: 24574066 [TBL] [Abstract][Full Text] [Related]
18. The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (μ-opioid receptor) knockout mice. Kögel B; De Vry J; Tzschentke TM; Christoph T Neurosci Lett; 2011 Mar; 491(2):104-7. PubMed ID: 21232580 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study. Baron R; Likar R; Martin-Mola E; Blanco FJ; Kennes L; Müller M; Falke D; Steigerwald I Pain Pract; 2016 Jun; 16(5):580-99. PubMed ID: 26095455 [TBL] [Abstract][Full Text] [Related]
20. Effect of tapentadol on neurons in the locus coeruleus. Torres-Sanchez S; Alba-Delgado C; Llorca-Torralba M; Mico JA; Berrocoso E Neuropharmacology; 2013 Sep; 72():250-8. PubMed ID: 23664814 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]